Cardiovascular Disease Risk In HIV-infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction among REPRIEVE Trial Participants

As discussed on REPRIEVE site calls and CROI/ACTG meetings and as delineated in protocol v3.0, Women’s Objectives have been fully integrated into the REPRIEVE Trial (A5332). The Women’s objectives will answer questions on sex-specific mechanisms of cardiovascular disease risk and risk reduction within the context of A5332. In order for these questions to be addressed, a modest amount of additional blood will be collected during select A5332 visits in which blood is already being drawn (entry, year 1, end-of-study), as per the A5332 LPC. Additional funds are being offered to cover costs related to drawing this additional blood, as well as to further support participant remuneration (further support of participant remuneration is at the discretion of individual sites/local IRB’s).